2. Search Result
Search Result
Results for "

ductal

" in MedChemExpress (MCE) Product Catalog:

83

Inhibitors & Agonists

10

Peptides

4

MCE Kits

4

Inhibitory Antibodies

7

Natural
Products

4

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1427
    Glycodeoxycholate Sodium
    3 Publications Verification

    Sodium glycyldeoxycholate

    		 Endogenous Metabolite Metabolic Disease
    Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .
    Glycodeoxycholate Sodium
  • HY-P99296
    Intetumumab

    CNTO 95; Anti-Human CD51 Recombinant Antibody

    		 Integrin Cancer
    Intetumumab (CNTO 95) is a humanized monoclonal antibody targeting CD51/αV-integrins. Intetumumab is used in the research of pancreatic ductal adenocarcinoma (PDAC) .
    Intetumumab
  • HY-109120
    Odevixibat
    3 Publications Verification

    A4250

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat
  • HY-144439
    HTS07545

    		Mitochondrial Metabolism Cardiovascular Disease Cancer
    HTS07545 is a potent sulfide:quinone oxidoreductase (SQOR) inhibitor with an IC50 of 30 nM. HTS07545 reduces the decomposition rate of hydrogen sulfide (H2S). HTS07545 can be used in the research of heart failure and pancreatic ductal adenocarcinoma.
    HTS07545
  • HY-169113
    EPZ032597

    		Histone Methyltransferase Cancer
    EPZ032597 is a selective and noncompetitive SMYD2 inhibitor with an IC50 value of 16 nM. EPZ032597 is promising for research of pancreatic ductal adenocarcinoma .
    EPZ032597
  • HY-N1427R
    Glycodeoxycholate Sodium (Standard)

    Sodium glycyldeoxycholate (Standard)

    		 Reference Standards Endogenous Metabolite Metabolic Disease
    Glycodeoxycholate (Sodium) (Standard) is the analytical standard of Glycodeoxycholate (Sodium). This product is intended for research and analytical applications. Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels[1][2][3].
    Glycodeoxycholate Sodium (Standard)
  • HY-147838
    Nampt-IN-9

    		NAMPT Cancer
    Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .
    Nampt-IN-9
  • HY-116212
    JCP-170

    		MAGL Cancer
    JCP-170, a substituted chloroisocoumarin, is an ABHD6 inhibitor. JCP-170 robustly and reproducibly inhibits metastatic seeding of the murine cell line 0688M and both human pancreatic ductal adenocarcinoma (PDAC) cell lines .
    JCP-170
  • HY-P1535
    Secretin, porcine

    Porcine secretin acetate

    		 Secretin Receptor Inflammation/Immunology
    Secretin, porcine (Porcine secretin acetate) is a 27-amino acid peptide, acting on pancreatic acinar cells and ductal epithelial cells stimulating the production of bicarbonate rich fluid.
    Secretin, porcine
  • HY-P1535A
    Secretin, porcine TFA

    Porcine secretin TFA

    		 Secretin Receptor Inflammation/Immunology
    Secretin, porcine TFA (Porcine secretin TFA) is a 27-amino acid peptide, acting on pancreatic acinar cells and ductal epithelial cells stimulating the production of bicarbonate rich fluid .
    Secretin, porcine TFA
  • HY-101194
    Tin protoporphyrin IX dichloride
    15+ Cited Publications

    Tin-protoporphyrin IX; Sn-Protoporphyrin; SnPPIX

    		 Reactive Oxygen Species (ROS) Cancer
    Tin protoporphyrin IX dichloride (SnPPIX) is a potent Heme oxygenase-1 (HO-1) inhibitor. Tin protoporphyrin IX dichloride sensitizes pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mice model .
    Tin protoporphyrin IX dichloride
  • HY-109120S
    Odevixibat-d5

    A4250-d5

    		 Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-d5
  • HY-109120R
    Odevixibat (Standard)

    		Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat (Standard)
  • HY-B1557
    Betazole
    1 Publications Verification

    Ametazole

    		 Histamine Receptor Metabolic Disease
    Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
    Betazole
  • HY-109120S1
    Odevixibat-13C6

    A4250-13C6

    		 Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds Metabolic Disease
    Odevixibat- 13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .
    Odevixibat-13C6
  • HY-B1557A
    Betazole dihydrochloride

    Ametazole dihydrochloride

    		 Histamine Receptor Metabolic Disease
    Betazole (Ametazole) dihydrochloride, a pyrazole analogue of histamine, is an orally active H2 receptor agonist. Betazole dihydrochloride induces gastric acid secretion, and causes an immediate and significant increase in common bile duct pressure. Betazole dihydrochloride has been used as a diagnostic agent known as histalog, for investigating gastric acid secretory capacity .
    Betazole dihydrochloride
  • HY-156027
    SIRT6-IN-3

    		Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK Neurological Disease Inflammation/Immunology Endocrinology Cancer
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .
    SIRT6-IN-3
  • HY-161346
    EBET-1055

    		PROTACs Epigenetic Reader Domain Cancer
    EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures . Pink: BET ligand (HY-161387); Blue: CRBN ligase ligand (HY-14658); Black: linker
    EBET-1055
  • HY-161346A
    (Rac)-EBET-1055

    		PROTACs Epigenetic Reader Domain Cancer
    (Rac)-EBET-1055 is the racemate of EBET-1055 (HY-161346). EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .
    (Rac)-EBET-1055
  • HY-19694
    BRD7552

    		Insulin Receptor Endocrinology
    BRD7552, a potent PDX1 transcription factor inducer, upregulates PDX1 expression in both primary human islets and ductal cells, and induces epigenetic changes in the PDX1 promoter consistent with transcriptional activation. BRD7552 increases insulin expression. PDX1 is a key transcription factor involved in pancreas development and β cell function .
    BRD7552
  • HY-B1557R
    Betazole (Standard)

    Ametazole (Standard)

    		 Reference Standards Histamine Receptor Metabolic Disease
    Betazole (Standard) is the analytical standard of Betazole. This product is intended for research and analytical applications. Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
    Betazole (Standard)
  • HY-155222
    TW9

    		Epigenetic Reader Domain HDAC Cancer
    TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with KDs of 0.069 μM, 0.231 μM for BRD4(1), BRD4(2), and an IC50 of 0.29 μM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 (HY-13030) and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026) .
    TW9
  • HY-151523
    KRas G12R inhibitor 1

    		Ras Cancer
    KRas G12R inhibitor 1 is a covalent inhibitor targeting the common oncogenic mutant KRas G12R with selectivity for the mutant arginine. KRas G12R inhibitor 1 possesses an α,β-diketoamide and exploits strong nucleophilicity of the mutant cysteine and irreversibly binds in the Switch II region of KRas. KRas G12R inhibitor 1 can be researched for K-Ras (G12R)-driven cancer such as pancreatic ductal adenocarcinoma (PDAC) .
    KRas G12R inhibitor 1
  • HY-148808
    Zelasudil

    RXC007

    		 ROCK Cancer
    Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .
    Zelasudil
  • HY-122723
    GOT1 inhibitor-1
    2 Publications Verification

    		 Reactive Oxygen Species (ROS) Cancer
    GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC50 of 8.2 uM. GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC) .
    GOT1 inhibitor-1
  • HY-P99379
    Nidanilimab (Nadunolimab)

    CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)

    		 Interleukin Related Cancer
    Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
    Nidanilimab (Nadunolimab)
  • HY-172177
    ROCK/HDAC-IN-2

    		Apoptosis HDAC ROCK Cancer
    ROCK/HDAC-IN-2 (Compound C-9) is a ROCK/HDAC inhibitor, with IC50 values of 0.185 µM, 0.8 µM, and 0.7 µM for HDAC6, ROCK1, and ROCK2, respectively. ROCK/HDAC-IN-2 can induce apoptosis and changes in mitochondrial membrane potential in cancer cells, demonstrating significant antitumor activity. ROCK/HDAC-IN-2 can be used in the research of pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) .
    ROCK/HDAC-IN-2
  • HY-172620
    LIB3S0280

    		IKK Akt Apoptosis Cancer
    LIB3S0280 is a potent TBK1 inhibitor with an IC50 value of 493.9 nM. LIB3S0280 can inhibit TBK1 downstream signaling by decreasing the phosphorylation of IκBα and AKT. LIB3S0280 leads to G2/M arrest and induces apoptosis in pancreatic cancer cells. LIB3S0280 shows significant inhibition against pancreatic cancer cell lines that highly express TBK1 with IC50 values of 6.64-10.98 μM at 96 h. LIB3S0280 has the potential for pancreatic ductal adenocarcinoma (PDAC) research .
    LIB3S0280
  • HY-175529
    KRASG12D-IN-7

    		Ras ERK Apoptosis Cancer
    KRASG12D-IN-7 is a selective KRAS G12D inhibitor. KRASG12D-IN-7 displays strong binding activity for KRAS G12D in both its GDP- and GTP- bound states, with Kd value of 1.12 nM and 1.86 nM, respectively. KRASG12D-IN-7 inhibits the proliferation of KRAS G12D harboring AsPC-1 cells with an IC50 value of 10 nM and suppresses MAPK signaling. KRASG12D-IN-7 induces G0/G1 phase arrest and apoptosis in AsPC-1 cells, and strongly inhibits their colony formation. KRASG12D-IN-7 can be used for the study of cancers harboring KRAS G12D mutation, particularly pancreatic ductal adenocarcinoma (PDAC) .
    KRASG12D-IN-7
  • HY-P10944
    Unlabeled FXX489

    NNS309

    		 FAP Cancer
    Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .
    Unlabeled FXX489
  • HY-100498
    GSK2256098
    5+ Cited Publications

    		 FAK Apoptosis Cancer
    GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    GSK2256098
  • HY-129085
    5-Methyl cromolyn disodium

    C5OH

    		 Others Cancer
    5-Methyl cromolyn (C5OH) disodium, an analog of Cromolyn (HY-B1619), is a S100P inhibitor. 5-Methyl cromolyn disodium inhibits the binding of S100P to its receptor RAGE, NF-κB activity and cell proliferation, and promotes Gemcitabine (HY-17026)-induced apoptosis. 5-Methyl cromolyn disodium reduces tumor growth and metastasis, and prolongs survival in mouse models of syngeneic PDAC. 5-Methyl cromolyn disodium can be used for pancreatic cancer like pancreatic ductal adenocarcinoma (PDAC) research .
    5-Methyl cromolyn disodium
  • HY-148260
    KRAS G12D inhibitor 16

    		Ras Cancer
    KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC50 value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .
    KRAS G12D inhibitor 16
  • HY-N15784
    Tauro-12-oxolithocholanoic acid sodium

    		Biochemical Assay Reagents Metabolic Disease
    Tauro-12-oxolithocholanoic acid sodium is a bile acid (BA) suitable to investigate BAs and their relatives’ behavior and correlation with liver, gallbladder, and bile ducts diseases.
    Tauro-12-oxolithocholanoic acid sodium
  • HY-A0190
    Caerulein
    Maximum Cited Publications
    110 Publications Verification

    Ceruletide; Cerulein; FI-6934

    		 Cholecystokinin Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Caerulein is a decapeptide and a potent cholecystokinin receptor agonist. Caerulein is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .
    Caerulein
  • HY-158722
    Caerulein acetate

    		Cholecystokinin Receptor Cardiovascular Disease Metabolic Disease Endocrinology
    Caerulein acetate is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide acetate is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts .
    Caerulein acetate
  • HY-160850
    C18 Ceramide-1-phosphate (d18:1/18:0) ammonium salt

    		Endogenous Metabolite Endocrinology
    C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) is a specific type of long-chain molecule found in murine skin . C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt) promotes migration of both mouse bone marrow-derived multipotent stromal cells and human umbilical vein endothelial cells at concentrations between 0.5-5 µM. C18 Ceramide-1-phosphate (d18:1/18:0) (ammonium salt)’s levels are higher in CFPAC-1 pancreatic ductal adenocarcinoma cells than in pancreatic cancer stem cells .
    C18 Ceramide-1-phosphate (d18:1/18:0) ammonium salt
  • HY-N15768
    Tauro-3β,5α,6β-trihydroxycholanoic acid sodium

    		Biochemical Assay Reagents Metabolic Disease
    Tauro-3β,5α,6β-trihydroxycholanoic acid sodium is a bile acid (BA) suitable to investigate BAs and their relatives’ behavior and correlation with liver, gallbladder, and bile ducts diseases.
    Tauro-3β,5α,6β-trihydroxycholanoic acid sodium
  • HY-P99555
    Tomaralimab

    OPN-305

    		 Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
    Tomaralimab
  • HY-120396
    LY 293284

    		5-HT Receptor Neurological Disease
    LY 293284 is a potent and selective 5-HT1A receptor agonist. LY 293284 results in a significant drop in core temperature and consumes more food in cholestasis rat induced by bile duct resection .
    LY 293284
  • HY-B0149S3
    Tranexamic acid-13C2,15N

    Cyclocapron-13C2,15N

    		 Isotope-Labeled Compounds Inflammation/Immunology
    Tranexamic acid- 13C2, 15N (Cyclocapron- 13C2, 15N) is the 13C2 and 15N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .
    Tranexamic acid-13C2,15N
  • HY-12838
    RO5454948
    1 Publications Verification

    Mirk-IN-1; Dyrk1B/A-IN-1

    		 DYRK Cancer
    RO5454948 (Compound 9) is the inhibitor for Dyrk1B and Dyrk1A with IC50 of 68 nM and 22 nM. RO5454948 exhibits cytotoxicity in cancer cell SW620 with EC50 of 1.9 μM .
    RO5454948
  • HY-N6237
    Aspulvinone O

    		Aminotransferases (Transaminases) Apoptosis Cancer
    Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces NADPH production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models .
    Aspulvinone O
  • HY-175202
    CIDD-8633

    		Discoidin Domain Receptor Apoptosis Caspase Interleukin Related PERK Cancer
    CIDD-8633 is a potent DDR2 inhibitor with an IC50 of 6.105 μM. CIDD-8633 inhibits cell migration and halts the cell cycle and induces apoptosis, significantly suppressing pancreatic ductal adenocarcinoma (PDAC) tumor growth. CIDD-8633 can be used for the study of pancreatic cancer such as PDAC .
    CIDD-8633
  • HY-160045
    AP1153 aptamer sodium

    		Cholecystokinin Receptor Cancer
    AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .
    AP1153 aptamer sodium
  • HY-136750
    Z-LLY-FMK

    Calpain Inhibitor IV

    		 Apoptosis Proteasome Parasite Cancer
    Z-LLY-FMK (Calpain Inhibitor IV) is a calpain inhibitor, involved in apoptosis of many cell systems. Z-LLY-FMK inhibits the intestine apoptosis after common bile duct ligation. Z-LLY-FMK reduces parasite burden in mice challenged with Taenia crassiceps cysts. Z-LLY-FMK can be used for the study of cysticercosis .
    Z-LLY-FMK
  • HY-139562
    BMS-986318

    		FXR Metabolic Disease
    BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis .
    BMS-986318
  • HY-137561A
    Bexotegrast hydrochloride

    PLN-74809 hydrochloride

    		 Integrin Inflammation/Immunology
    Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .
    Bexotegrast hydrochloride
  • HY-W747072
    3-Sulfo-taurocholic Acid Disodium Salt

    3-Sulfocholyl Taurine; TCA3S

    		 Drug Metabolite Metabolic Disease
    3-Sulfo-taurocholic Acid Disodium Salt (3-Sulfocholyl Taurine; TCA3S) is a metabolite of the conjugated bile acid taurocholic acid. Plasma levels of 3-Sulfo-taurocholic Acid Disodium Salt are elevated in wild-type and Sortilin 1 (Sort1) knockout mice at 6 hours following bile duct ligation (BDL) and are further elevated in Sort1 knockout mice at 24 hours post-BDL.
    3-Sulfo-taurocholic Acid Disodium Salt
  • HY-15211
    MRK 003

    		γ-secretase Apoptosis Neurological Disease Cancer
    MRK 003 is a potent, selective and orally active γ-secretase inhibitor. MRK 003 reduce brain Aβ production in vivo. MRK 003 induces caspase-dependent apoptosis and inhibits tumor cell proliferation in vivo and in vitro .
    MRK 003

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: